| Antibody HPA037503 | Antibody HPA037504 | |||
|---|---|---|---|---|
| ANTIBODY INFORMATION | ||||
| Provider | Atlas Antibodies Sigma-Aldrich |
Atlas Antibodies Sigma-Aldrich |
||
| Product name | HPA037503 | HPA037504 | ||
| Host species | Rabbit | Rabbit | ||
|
Clonalityi The antibodies are designated mAB for monoclonal and pAb for polyclonal. |
pAb | pAb | ||
| Concentration | 0.0282 mg/ml | 0.1083 mg/ml | ||
| Purity | Affinity purified using the PrEST-antigen as affinity ligand | Affinity purified using the PrEST-antigen as affinity ligand | ||
|
Released in versioni The release of the Human Protein Atlas in which the antibody was first published. |
7.0 | 7.0 | ||
| Validation summaryi | ||||
|
IMMUNOCYTOCHEMISTRYi Immunocytochemistry is used to validate the antibody staining and for assessing and validating the protein expression pattern in selected human cell lines. |
||||
|
Validationi Results of validation by standard or enhanced validation. Standard validation is based on concordance with available experimental gene/protein characterization data in the UniProtKB/Swiss-Prot database. Standard validation results in scores Supported, Approved or Uncertain. Enhanced validation is performed using either siRNA knockdown, tagged GFP cell lines or independent antibodies. For the siRNA validation the decrease in antibody-based staining intensity upon target protein downregulation is evaluated. For the GFP validation the signal overlap between the antibody staining and the GFP-tagged protein is evaluated. For the independent antibodies validation the evaluation is based on comparison of the staining of two (or more) independent antibodies directed towards independent epitopes on the protein. For all cases except the siRNA validation, an image representative of the antibody staining pattern is shown. For the siRNA validation, a box plot of the results is shown. |
N/A |
Antibody validation by siRNA-mediated knock-down of the corresponding gene. Enhanced validation is given upon >25% reduction in relative fluorescence intensity in siRNA-treted cells versus negative control. Reliability scores for antibodies used in immunocytochemistry are set by comparing the staining pattern in cell lines with external experimental evidence for protein localization. The scores are termed Supported, Approved and Uncertain. The subcellular location is supported by literature.Immunofluorescent staining of human cell line U2OS shows localization to nucleoplasm and nuclear bodies. |
||
| Antibody dilution | human cell lines: A-431 fixed with PFA, dilution: 1:54 human cell lines: U-251MG fixed with PFA, dilution: 1:54 human cell lines: U2OS fixed with PFA, dilution: 1:54 siRNA assay: U2OS tested with dilution: 1:54 |
|||
|
IMMUNOHISTOCHEMISTRYi Immunohistochemistry is used for validating antibody reliability by assessing staining pattern in 45 normal tissues. Validation scores include Enhanced, Supported, Approved and Uncertain. |
||||
|
Validationi Results of validation by standard or enhanced validation based on assessment of antibody performance in 45 normal tissues. Standard validation results in scores Supported, Approved or Uncertain. An image representative of the antibody staining pattern is shown. Enhanced validation results in the score Enhanced and includes two methods: Orthogonal validation and Independent antibody validation. For orthogonal validation, representative images of high and low expression are shown. For independent antibody validation, four images of each independent antibody are displayed. |
![]() Protein distribution across 45 tissues similar between the independent antibodies HPA037503 and HPA037504. |
![]() Protein distribution across 45 tissues similar between the independent antibodies HPA037503 and HPA037504. |
||
|
Retrievali Antigen retrieval is a method used to restore/retrieve the epitope (antibody bidning region) of the target protein, cross-linked, and thus masked, during tissue preserving fixative treatment of the tissues. |
HIER pH6 | HIER pH6 | ||
| Antibody dilution | 1:13 | 1:125 | ||
|
Literature conformityi Conformance of the expression pattern with available gene/protein characterization data in scientific literature and data from bioinformatic predictions. UniProt is used as the main source of gene/protein characterization data and when relevant, available publications and other sources of information are researched in depth. Extensive or sufficient gene/protein data requires that there is evidence of existence on a protein level and that a substantial quantity of published experimental data is available from literature and public databases. Limited protein/gene characterization data does not require evidence of existence on a protein level and refers to genes for which only bioinformatic predictions and scarce published experimental data is available. |
Consistent with extensive gene/protein characterization data. | Consistent with extensive gene/protein characterization data. | ||
|
RNA consistencyi Consistency between immunohistochemistry data and consensus RNA levels is divided into five different categories: i) High consistency, ii) Medium consistency, iii) Low consistency, iv) Very low consistency, and v) Cannot be evaluated. |
Medium consistency between antibody staining and RNA expression data. | Medium consistency between antibody staining and RNA expression data. | ||
|
WESTERN BLOTi A Western blot analysis is performed on a panel of human tissues and cell lines to evaluate antibody specificity. For antibodies with unreliable result a revalidation using an over-expression lysate is performed. |
||||
|
Validationi Western Blot is used for quality control of the polyclonal antibodies generated in the project. After purification, the antibodies are used to detect bands in a setup of lysate and different tissues. The result is then scored Enhanced, Supported, Approved, or Uncertain. Enhanced validation includes five different methods: Genetic validation, Recombinant expression validation, Independent antibody validation, Orthogonal validation and Capture MS validation. |
This method is based on over-expression of the target protein in a cell line preferably not expressing the target protein. The staining of the antibody is evaluated by Western blot through analyses of samples from cell lysates with and without recombinant expression of the target protein. The results show no or weak band from the unmodified cell line lysate and a strong band in the cell line with recombinant expression. ![]() Band of predicted size in kDa (+/-20%) with additional bands present.
Lane 1: Marker [kDa] 250, 130, 95, 72, 55, 36, 28, 17, 10
Lane 2: Negative control (vector only transfected HEK293T lysate) Lane 3: Over-expression Lysate (Co-expressed with a C-terminal myc-DDK tag (~3.1 kDa) in mammalian HEK293T cells, LY414063) Target mass (kDa): 79.7 |
This method is based on over-expression of the target protein in a cell line preferably not expressing the target protein. The staining of the antibody is evaluated by Western blot through analyses of samples from cell lysates with and without recombinant expression of the target protein. The results show no or weak band from the unmodified cell line lysate and a strong band in the cell line with recombinant expression. ![]() Band of predicted size in kDa (+/-20%) with additional bands present.
Lane 1: Marker [kDa] 250, 130, 95, 72, 55, 36, 28, 17, 10
Lane 2: Negative control (vector only transfected HEK293T lysate) Lane 3: Over-expression Lysate (Co-expressed with a C-terminal myc-DDK tag (~3.1 kDa) in mammalian HEK293T cells, LY414063) Target mass (kDa): 79.7, 61.3 |
||
| Antibody dilution | 1:250 |
1:250 |
||
| PROTEIN ARRAY | ||||
|
Validationi A protein array containing 384 different antigens including the antibody target is used to analyse antibody specificity. Depending on the array interaction profile the antibody is scored as Supported, Approved, or Uncertain. |
||||
| Antibody dilution | 1:500 | 1:3000 | ||
| ANTIGEN INFORMATION | ||||
| Antigen | Recombinant protein fragment | Recombinant protein fragment | ||
| Length (aa) | 95 | 91 | ||
| Antigen sequence | PVFENVNVKSFDRCTGHSAEHTQCGKPQESTGRGSAFLKAVQGSGDTSRH
CLPTLADAKGLQDTGGTVNYFWGIPFCPDGVDPNQYTKVILCQLE
|
LLRKAIAESLNSCRPSDASATRSRPLATGPSSQSHQEKTTDSGLTEGIWQ
LVPPSLFKGSHISQGNEAEEREEPWDHTEKTEEEPVSGSSG
|
||
| Matching transcripts | UIMC1-201 - ENSP00000366434 [100%] UIMC1-212 - ENSP00000421926 [100%] |
UIMC1-201 - ENSP00000366434 [100%] UIMC1-207 - ENSP00000427480 [100%] UIMC1-212 - ENSP00000421926 [100%] |
||
| Matching mouse transcripts | ENSMUSP00000026997 [84%] ENSMUSP00000122196 [84%] ENSMUSP00000116839 [23%] ENSMUSP00000151458 [22%] |
ENSMUSP00000122196 [82%] ENSMUSP00000026997 [81%] ENSMUSP00000102093 [31%] ENSMUSP00000105312 [29%] ENSMUSP00000097095 [19%] |
||
ANTIGEN VIEWi The Protein BrowserThe ProteinBrowser displays the antigen location on the target protein(s) and the features of the target protein. Transcript names and schematic transcript structures including exons, introns and UTRs for the different isoforms are shown on top, and can be used to switch between the structures for the different splice variants. At the top of the view, the position of the antigen (identified by the corresponding HPA identifier) is shown as a green bar. A yellow triangle on the bar indicates a <100% sequence identity to the protein target. Below the antigens, the maximum percent sequence identity of the protein to all other proteins from other human genes is displayed, using a sliding window of 10 aa residues (HsID 10) or 50 aa residues (HsID 50). The region with the lowest possible identity is always selected for antigen design, with a maximum identity of 60% allowed for designing a single-target antigen (read more). The curve in blue displays the predicted antigenicity i.e. the tendency for different regions of the protein to generate an immune response, with peak regions being predicted to be more antigenic.The curve shows average values based on a sliding window approach using an in-house propensity scale. (read more). Signal peptides (turquoise) and membrane regions (orange) based on predictions using the majority decision methods MDM and MDSEC are also displayed. Low complexity regions are shown in yellow and InterPro regions in green. Common (purple) and unique (grey) regions between different splice variants of the gene are also displayed (read more), and at the bottom of the protein view is the protein scale. |
||||
|
|
||||
|
UIMC1-201 UIMC1-207 UIMC1-212 |
||||
Contact
The Project
The Human Protein Atlas
SUMMARY
TISSUE
BRAIN
SINGLE CELL
SUBCELL
CANCER
BLOOD
CELL LINE
STRUCTURE
INTERACTION